DK1147181T3 - Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser - Google Patents

Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser

Info

Publication number
DK1147181T3
DK1147181T3 DK00917613T DK00917613T DK1147181T3 DK 1147181 T3 DK1147181 T3 DK 1147181T3 DK 00917613 T DK00917613 T DK 00917613T DK 00917613 T DK00917613 T DK 00917613T DK 1147181 T3 DK1147181 T3 DK 1147181T3
Authority
DK
Denmark
Prior art keywords
cells
reverse transcriptase
telomerase
tert
telomerase reverse
Prior art date
Application number
DK00917613T
Other languages
English (en)
Inventor
Gregg B Morin
Serge Lichtsteiner
Alain Vasserot
Robert Adams
Lisa M Cardoza
Jane S Lebkowski
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/244,438 external-priority patent/US6777203B1/en
Application filed by Geron Corp filed Critical Geron Corp
Application granted granted Critical
Publication of DK1147181T3 publication Critical patent/DK1147181T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
DK00917613T 1999-02-04 2000-02-04 Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser DK1147181T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/244,438 US6777203B1 (en) 1997-11-19 1999-02-04 Telomerase promoter driving expression of therapeutic gene sequences

Publications (1)

Publication Number Publication Date
DK1147181T3 true DK1147181T3 (da) 2004-09-20

Family

ID=22922772

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00917613T DK1147181T3 (da) 1999-02-04 2000-02-04 Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser

Country Status (8)

Country Link
EP (1) EP1147181B1 (da)
AT (1) ATE266720T1 (da)
AU (1) AU761567B2 (da)
CA (1) CA2362367C (da)
DE (1) DE60010654T2 (da)
DK (1) DK1147181T3 (da)
ES (1) ES2220448T3 (da)
WO (1) WO2000046355A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449851T1 (de) 1996-10-01 2009-12-15 Geron Corp Menschlicher telomerase reverse transcriptase promoter
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6777203B1 (en) 1997-11-19 2004-08-17 Geron Corporation Telomerase promoter driving expression of therapeutic gene sequences
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
DE19947668A1 (de) * 1999-10-04 2001-04-19 Univ Eberhard Karls Tumorspezifischer Vektor für die Gentherapie
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US6921665B2 (en) 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
WO2002053760A2 (en) * 2000-12-18 2002-07-11 Geron Corporation Chimeric cytolytic viruses for cancer treatment
EP1377672A2 (en) 2001-02-23 2004-01-07 Novartis AG Vector constructs
AU2002242538B2 (en) * 2001-03-21 2007-06-28 Geron Corporation Animal tissue with carbohydrate antigens compatible for human transplantation
WO2003000916A2 (en) * 2001-06-21 2003-01-03 Sierra Sciences, Inc. Telomerase expression repressor proteins and methods of using the same
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
CA2490863A1 (en) * 2002-06-27 2004-01-08 Geron Corporation Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
US8163892B2 (en) 2002-07-08 2012-04-24 Oncolys Biopharma, Inc. Oncolytic virus replicating selectively in tumor cells
JP3867968B2 (ja) * 2002-07-08 2007-01-17 関西ティー・エル・オー株式会社 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
KR100523028B1 (ko) * 2003-02-27 2005-10-20 윤채옥 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터
US7153650B2 (en) 2003-03-13 2006-12-26 Geron Corporation Marker system for preparing and characterizing high-quality human embryonic stem cells
US7598077B2 (en) 2003-06-05 2009-10-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for enhancing differential expression
US7534585B2 (en) 2003-07-21 2009-05-19 Transgene S.A. Multifunctional cytokines
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
JP4635196B2 (ja) * 2005-03-04 2011-02-16 国立大学法人広島大学 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法
KR20070111542A (ko) 2005-03-09 2007-11-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 치료유전자의 종양-특이적, 발현 고효율을 위한 신규한ｈＴＭＣ 프로모터 및 벡터
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
HUE025015T2 (en) 2009-01-20 2016-04-28 Transgene Sa Soluble in ICAM-1 as a biomarker for predicting therapeutic response
AU2010227611B2 (en) 2009-03-24 2014-05-29 Transgene Sa Biomarker for monitoring patients
BRPI1010512A2 (pt) 2009-04-17 2016-03-15 Transgène S A "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
WO2011003905A1 (en) 2009-07-10 2011-01-13 Transgene Sa Biomarker for selecting patients and related methods
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
US9846157B2 (en) 2012-10-26 2017-12-19 The Trustees Of The University Of Pennsylvania Compositions, methods and microfluidics device for telomerase based in vitro diagnostic assays for detecting circulating tumor cells (CTC)
US10941452B2 (en) 2014-10-06 2021-03-09 The Trustees Of The University Of Pennsylvania Compositions and methods for isolation of circulating tumor cells (CTC)
CN114703186B (zh) * 2022-03-31 2023-08-29 四川大学 肿瘤特异性启动子及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
ATE449851T1 (de) * 1996-10-01 2009-12-15 Geron Corp Menschlicher telomerase reverse transcriptase promoter
DE19757984A1 (de) * 1997-12-24 1999-07-01 Bayer Ag Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung

Also Published As

Publication number Publication date
DE60010654D1 (de) 2004-06-17
WO2000046355A2 (en) 2000-08-10
WO2000046355A3 (en) 2000-11-30
CA2362367C (en) 2004-08-03
AU3856300A (en) 2000-08-25
DE60010654T2 (de) 2005-06-16
ATE266720T1 (de) 2004-05-15
EP1147181B1 (en) 2004-05-12
CA2362367A1 (en) 2000-08-10
WO2000046355A9 (en) 2001-10-04
EP1147181A2 (en) 2001-10-24
ES2220448T3 (es) 2004-12-16
AU761567B2 (en) 2003-06-05
WO2000046355A8 (en) 2001-07-05
WO2000046355B1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
DK1147181T3 (da) Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser
IL160132A0 (en) Methods and compositions relating to improved lentiviral vector production systems
AR001830A1 (es) Terapia genetica por medio del uso de vectores adenovirales
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
AU8692598A (en) A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
FI951404A0 (fi) Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän, erityisesti aivojen, soluihin
IL181876A0 (en) Telomelysin-gfp gene-containing recombinant virus
DK0777740T3 (da) Genterapeutisk behandling af sygdomme i centralnervesystemet (CNS) med et cellespecifikt, cellecyklusafhængigt virksomt sto
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
AR024771A1 (es) Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes
EP1368467A4 (en) Putrescine N-METHYLTRANSFERASEPROMOTOR
AU2002364302A8 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
DE69730153D1 (de) EHV-1 Vektoren
ATE384796T1 (de) Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor
Wildner Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.
FR2680518B1 (da)
ATE286908T1 (de) Gewebespezifische expression des retinoblastoma- proteins
ATE473763T1 (de) Replizierende adenovirus-vektoren
Hsieh et al. The potential role of gene therapy in the treatment of bladder cancer
WO2004024867A3 (en) Vigilant vector system
ATE498687T1 (de) Zellspezifischer expressions-/replikationsvektor
Lefranc et al. γδ lineage‐specific transcription of human T cell receptor γ genes by a combination of a non‐lineage‐specific enhancer and silencers
Curiel Conditionally Replicative Adenovirus for Prostate Cancer Therapy
DK0979093T3 (da) Terapeutisk virusmiddel, hvis udvikling kan standses